References
- 1. Vardiman JW, Arber DA, Brunning RD, Larson RA, Matutes E, Baumann I, et al. Therapy - related myeloid neoplasms in: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. Fourth Ed. Lyon France: IARC Press 2008: 127-129.
- 2. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Michelle M, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391-2405. DOI: 10.1182/blood-2016-03-64354410.1182/blood-2016-03-64354427069254
- 3. Larson RA. Therapy - related myeloid neoplasms. Haematologica 2009 April;94(4):454-9. DOI: 10.3324/ haematol.2008.00515710.3324/haematol.2008.005157266360719336749
- 4. Heuser M. Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment? Hematology Am Soc Hematol Educ Program. 2016 Dec;(1):24-32. DOI: 10.1182/asheducation-2016.1.2410.1182/asheducation-2016.1.24614251427913458
- 5. Churpek JE, Marquez R, Neistadt B, Claussen K, Lee MK, Churpek MM, et al. Inherited mutations in cancer succeptibility genes are common among survivors of breast cancer who develop therapy - related leukemia. Cancer. 2016 Jan;122(2):304-11. DOI: 10.1002/ cncr.2961510.1002/cncr.29615470798126641009
- 6. Kayser S, Dohner K, Krauter J, Köhne CH, Horst HA, Held G, et al. The impact of therapy - related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011 Feb; 117(7):2137-45. DOI: 10.1182/blood-2010-08-30171310.1182/blood-2010-08-30171321127174
- 7. Montesinos P, Gonzalez JD, Gonzalez J, Rayo’n C, de Lisa E, Amigo ML, et al. Therapy - Related Myeloid Neoplasms in patients with acute promyelocytic leukemia treated with all- trans retinoic acid and anthracycline based chemotherapy. J Clin Oncol. 2010 Aug;28(24):3872-9. DOI: 10.1200/JCO.2010.29.226810.1200/JCO.2010.29.226820625122
- 8. Lo-Coco F, Cicconi L, Breccia M. Current standard treatment of acute promyelocytic leukemia. British Journal of Haematology. 2016 Mar;172(6):841-4. DOI: 10.1111/bjh.1389010.1111/bjh.1389026687281
- 9. Zeidan AM, Gore SD. New strategies in acute promyelocytic leukemia: Moving to an Entirely Oral, Chemotherapy-Free Upfront Management Approach. Clinical Cancer Research. 2014 Oct; 20(19):4985-93. DOI: 10.1158/1078-0432.CCR-13-272510.1158/1078-0432.CCR-13-2725488275825274377
- 10. Tomita A, Kiyoi H, NaoeT. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia. Int J Hematol. 2013 Jun;97(6):717-25. DOI: 10.1007/ s12185-013-1354-410.1007/s12185-013-1354-423670176
- 11. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008 March; 111(5):2505-14. DOI: 10.1182/blood-2007-07-10279810.1182/blood-2007-07-10279818299451
- 12. Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayón C, Barbui T, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000 Aug; 96:1247-53.
- 13. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommandations from an expert panel on behalf of the European Leukemia Net. Blood 2009 Feb;113(9):1875-91. DOI: 10.1182/ blood-2008-04-15025010.1182/blood-2008-04-150250
- 14. Sanz MA, Lo-Coco F. Modern Approaches to Treating Acute Promyelocytic Leukemia. J Clin Oncol. 2011 Feb;29(5):495-503. DOI: 10.1200/JCO.2010.32.106710.1200/JCO.2010.32.1067
- 15. Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood 2010 Oct; 116(17):3171-9. DOI: 10.1182/ blood-2010-03-27619610.1182/blood-2010-03-276196
- 16. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. N Engl J Med 2013 Jul;369(2):111-21. DOI: 10.1056/ NEJMoa130087410.1056/NEJMoa1300874
- 17. Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, et al. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J Clin Oncol 2016 Jul;1-14.
- 18. Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. The Lancet Oncology 2015 Oct;16(13): 1295-305. DOI: 10.1016/S1470-2045(15)00193-X10.1016/S1470-2045(15)00193-X
- 19. Imagawa J, Harada Y, Shimomura T, Tanaka H, Okikawa Y, Hyodo H, et al. Clinical and genetic features of therapy-related myeloid neoplasms after chemotherapy for acute promyelocytic leukemia. Blood 2010 Dec; 116(26):6018-22. DOI: 10.1182/ blood-2010-06-28938910.1182/blood-2010-06-289389
- 20. Eghtedar A, Rodriquez I, Kantarjian H, O’Brien S, Daver N, Manero GG, et al. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid pluss arsenic trioxide. Leuk. Lymphoma 2015 May;56(5):1342-5. DOI: 10.3109/10428194.2014.95314310.3109/10428194.2014.953143
- 21. Latagliata R, Petti MC, Fenu S, Mancini M, Spiriti MAE, Breccia M, et al. Therapy-related myelodysplastic syndrome- acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 2002 Feb; 99(3):822-4. DOI: 10.1182/blood.V99.3.82210.1182/blood.V99.3.822
- 22. Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, et al. Risk-adapted treatment of acute promyelocytic leukemia based on alltrans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood.2010 Jun;115(25):5137-46. DOI: 10.1182/ blood-2010-01-26600710.1182/blood-2010-01-266007
- 23. Panizo C, Patino A, Lecumberri R, Calasanz MJ, Odero MD, Bendandi M, et al. Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: clinical and genetic features of two cases. Cancer Genetics and Cytogenetics 2003 Jul; 143(2):178-81. DOI: 10.1016/S0165-4608(02)00859-210.1016/S0165-4608(02)00859-2
- 24. Lobe I, Rigal-Huguet F, Vekhoff A, Desablens B, Bordessoule D, Mounier C, et al. Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience. Leukemia. 2003 Aug;17(8):1600-4. DOI: 10.1038/sj.leu.240303410.1038/sj.leu.240303412886249
- 25. Coliţă A, Nicoară S, Butoianu E, Munteanu N, Ursea C, Poppa C, et al. Acute promyelocytic leukemia. A study of 119 cases and a review of the literature. Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna. 1988 Jan-Feb;40(1):21-32.
- 26. Colita A, Vasilache D, Gheorghe A, Jardan C, Jardan D, Dragomir M, et al. Acute promyelocytic leukemia: the importance of the laboratory examination for the diagnosis and the dynamic following of the answer to the treatment. Romanian Review of the Laboratory Medicine 2013 Jun; 21(2/4):S60.
- 27. Coombs CC, Tavakkoli M, Tallman MS: Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer Journal 2015 Feb;5, e304. DOI: 10.1038/bcj.2015.2510.1038/bcj.2015.25445032525885425
- 28. Schmiegelow K, Al - Modhwahii, Andersen MK, Behrendtz M, Forestier E, Hasle H, et al. Methotrexate (6- mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia. Results from the NOPHO ALL- 92 study. Blood 2009;113:6077-884. DOI: 10.1182/blood-2008-11-18788010.1182/blood-2008-11-187880269923019224761
- 29. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017 Jan;129(4):424-47. DOI: 10.1182/blood-2016-08-73319610.1182/blood-2016-08-733196529196527895058
- 30. Watts JM, Tallman MS. Acute promyelocytic leukemia: What is the new standard of care? Blood Rev 2014 Sep; 28(5):205-12. DOI: 10.1016/j.blre.2014.07.00110.1016/j.blre.2014.07.00125107311
- 31. Esteve J, Escoda L, Martín G, Rubio V, Díaz- Mediavilla J, González M, et al. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracyclinebased chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. Leukemia 2007 Mar;21(3):446-52. DOI: 10.1038/sj.leu.2404501 10.1038/sj.leu.240450117205057